Physician profile
Bipin Patel
NPI 1356453914
$13,402.02
in general payments reported to CMS, 2019-2025
60 companies · $74.34 in 2025
The $74.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,854 · 2020: $1,512 · 2021: $2,770 · 2022: $2,065 · 2023: $2,701 · 2024: $2,426 · 2025: $74.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,200.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,164.40 | 2019-2024 | |
| Sk Life Science, INC. | $1,037.14 | 2020-2024 | Xcopri |
| Ucb, INC. | $752.94 | 2019-2024 | Briviact, Fintepla |
| Lundbeck LLC | $628.54 | 2020-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $478.03 | 2019-2024 | |
| Amgen INC. | $459.08 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $452.06 | 2019-2024 | Austedo Xr |
| Eisai INC. | $428.86 | 2019-2024 | |
| Allergan, INC. | $405.82 | 2019-2022 | |
| Neurelis, INC. | $392.70 | 2020-2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $384.97 | 2019-2022 | |
| Lilly USA, LLC | $378.15 | 2021-2024 | Amyvid, Emgality, Kisunla |
| Pfizer INC. | $374.97 | 2020-2024 | |
| Jazz Pharmaceuticals INC. | $373.55 | 2019-2024 | |
| Greenwich Biosciences, INC. | $373.33 | 2019-2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bipin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.